EA
ALXN

Emerald Acquisition’s Alexion Pharmaceuticals ALXN Stock Holding History

Emerald Acquisition’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$13.7M Buy
111,421
+1,999
+2% +$257K 0.03% 705
2016
Q2 		$12.8M Buy
+109,422
New +$15.5M 0.02% 809

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Emerald Acquisition's ALXN Position: Q3 2016 in Review

Emerald Acquisition increased its Alexion Pharmaceuticals (ALXN) stake by 1.8% in Q3 2016, buying an estimated $257K and bringing the position to 111,421 shares worth $13.7M. The position accounts for 0.03% of the portfolio, ranked #705.

Emerald Acquisition first reported a position in ALXN in Q2 2016 and has held it in 2 quarters since. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Emerald Acquisition held 111,421 shares of Alexion Pharmaceuticals worth $13.7M as of Q3 2016.
  • Emerald Acquisition bought 1,999 Alexion Pharmaceuticals shares in Q3 2016, an estimated $257K.
  • Alexion Pharmaceuticals made up 0.03% of Emerald Acquisition's portfolio in Q3 2016, its #705 holding.
  • Emerald Acquisition first reported a position in Alexion Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.